Literature DB >> 10360395

Descriptive analysis of tibial pseudarthrosis in patients with neurofibromatosis 1.

D A Stevenson1, P H Birch, J M Friedman, D H Viskochil, P Balestrazzi, S Boni, A Buske, B R Korf, M Niimura, E K Pivnick, E K Schorry, M P Short, R Tenconi, J H Tonsgard, J C Carey.   

Abstract

Five percent of individuals with neurofibromatosis type 1 (NF1) present with congenital long bone pseudarthrosis (PA). In large series, 50-80% of patients with congenital long bone PA also have NF1. Very little information exists on the natural history and pathogenesis of PA in NF1. This report is a descriptive analysis of a large series of patients with NF1 and tibial bowing or PA. Study A is a case-control study using the National Neurofibromatosis Foundation International Database (NNFFID). Eighty-five patients with PA were compared to a control group from the same database. There was a statistically significant male predominance of NF1 cases with PA (54 males to 31 females), compared to controls (85 males to 87 females) (chi2 = 4.0, P = 0.046, using a two-tailed test with Yates' correction). There was no significant difference in the clinical presentation of NF1 manifestations in NF1 patients with PA than in NF1 patients without PA. Of the affected individuals with PA, there were 24 de novo cases and 21 familial cases (9 through maternal and 12 through paternal inheritance). Questions that could not be answered by Study A were addressed by a partially overlapping case-series report, Study B, in which data on 75 cases ascertained through questionnaires completed by NF center directors were collected. From Study B we determined that half of the patients who had a fracture sustained it before age 2, and approximately 16% of the pseudarthrosis patients had an amputation. Our data indicate a male predominance and no parent-of-origin effect. Male gender may be a susceptibility factor for pseudarthrosis in NF1.

Entities:  

Mesh:

Year:  1999        PMID: 10360395     DOI: 10.1002/(sici)1096-8628(19990611)84:5<413::aid-ajmg5>3.0.co;2-1

Source DB:  PubMed          Journal:  Am J Med Genet        ISSN: 0148-7299


  40 in total

Review 1.  A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor.

Authors:  Nancy Ratner; Shyra J Miller
Journal:  Nat Rev Cancer       Date:  2015-04-16       Impact factor: 60.716

2.  Mice lacking Nf1 in osteochondroprogenitor cells display skeletal dysplasia similar to patients with neurofibromatosis type I.

Authors:  Weixi Wang; Jeffry S Nyman; Koichiro Ono; David A Stevenson; Xiangli Yang; Florent Elefteriou
Journal:  Hum Mol Genet       Date:  2011-07-14       Impact factor: 6.150

3.  Bone resorption in syndromes of the Ras/MAPK pathway.

Authors:  D A Stevenson; E L Schwarz; J C Carey; D H Viskochil; H Hanson; S Bauer; H-Y Cindy Weng; T Greene; K Reinker; J Swensen; R J Chan; F-C Yang; L Senbanjo; Z Yang; R Mao; M Pasquali
Journal:  Clin Genet       Date:  2011-01-19       Impact factor: 4.438

Review 4.  Malignant Peripheral Nerve Sheath Tumors: From Epigenome to Bedside.

Authors:  Justin Korfhage; David B Lombard
Journal:  Mol Cancer Res       Date:  2019-04-25       Impact factor: 5.852

5.  Double inactivation of NF1 in tibial pseudarthrosis.

Authors:  David A Stevenson; Holly Zhou; Shadi Ashrafi; Ludwine M Messiaen; John C Carey; Jacques L D'Astous; Stephen D Santora; David H Viskochil
Journal:  Am J Hum Genet       Date:  2006-05-10       Impact factor: 11.025

6.  ATF4 mediation of NF1 functions in osteoblast reveals a nutritional basis for congenital skeletal dysplasiae.

Authors:  Florent Elefteriou; M Douglas Benson; Hideaki Sowa; Michael Starbuck; Xiuyun Liu; David Ron; Luis F Parada; Gerard Karsenty
Journal:  Cell Metab       Date:  2006-12       Impact factor: 27.287

7.  Neurofibromin deficiency-associated transcriptional dysregulation suggests a novel therapy for tibial pseudoarthrosis in NF1.

Authors:  Nandina Paria; Tae-Joon Cho; In Ho Choi; Nobuhiro Kamiya; Kay Kayembe; Rong Mao; Rebecca L Margraf; Gerlinde Obermosser; Ila Oxendine; David W Sant; Mi Hyun Song; David A Stevenson; David H Viskochil; Carol A Wise; Harry K W Kim; Jonathan J Rios
Journal:  J Bone Miner Res       Date:  2014-12       Impact factor: 6.741

8.  Loss of Y chromosome in the malignant peripheral nerve sheet tumor of a patient with Neurofibromatosis type 1.

Authors:  Seon-Yong Jeong; Sang-Jin Park; Su-Jin Lee; Ho-Jin Park; Hyon J Kim
Journal:  J Korean Med Sci       Date:  2010-04-16       Impact factor: 2.153

9.  Health-related quality of life measures in genetic disorders: an outcome variable for consideration in clinical trials.

Authors:  David A Stevenson; John C Carey
Journal:  Am J Med Genet C Semin Med Genet       Date:  2009-08-15       Impact factor: 3.908

10.  Hyperactive transforming growth factor-β1 signaling potentiates skeletal defects in a neurofibromatosis type 1 mouse model.

Authors:  Steven D Rhodes; Xiaohua Wu; Yongzheng He; Shi Chen; Hao Yang; Karl W Staser; Jiapeng Wang; Ping Zhang; Chang Jiang; Hiroki Yokota; Ruizhi Dong; Xianghong Peng; Xianlin Yang; Sreemala Murthy; Mohamad Azhar; Khalid S Mohammad; Mingjiang Xu; Theresa A Guise; Feng-Chun Yang
Journal:  J Bone Miner Res       Date:  2013-12       Impact factor: 6.741

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.